-
1 week ago | 
pipelinereview.com | Ulrich Martin
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has...
-
1 week ago | 
pipelinereview.com | Ulrich Martin
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, PA, USA I May 9, 2025 I Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the...
-
1 week ago | 
pipelinereview.com | Ulrich Martin
SHANGHAI, China I May 9, 2025 I Minghui Pharmaceutical (“Minghui”), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical (“Qilu”) for the development, manufacturing, and commercialization of its B7-H3 ADC (MHB088C) in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan).
-
1 week ago | 
pipelinereview.com | Ulrich Martin
Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs.
-
1 week ago | 
pipelinereview.com | Ulrich Martin
Temtokibart achieved positive results for the primary endpoint for the 3 highest doses in a phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis (AD) Temtokibart – also called LEO 138559 – is an investigational IL-22RA1 antagonist BALLERUP, Denmark I May 09, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with temtokibart, an investigational IL-22RA1 antagonist, for the potential treatment of...
-
1 week ago | 
pipelinereview.com | Ulrich Martin
AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as “AVMAPKI FAKZYNJA CO-PACK” Accelerated approval, well ahead of the June 30, 2025 PDUFA action date, was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS mutant recurrent LGSOC Verastem to host investor conference call and webcast today at 2:30 pm ET BOSTON, MA, USA I May 08, 2025 I Verastem Oncology...
-
1 week ago | 
pipelinereview.com | Ulrich Martin
Study will evaluate OX-4224 as a second-line monotherapy in patients with PD-L1–positive non-small cell lung cancer, expanding potential access to checkpoint inhibitors in low-resource settings SAN DIEGO, CA, USA I May 08, 2025 I OmRx Oncology, or “OmRx,” a clinical-stage biopharmaceutical venture dedicated to expanding access to cancer immunotherapy worldwide, today announced the initiation of a Phase 2 clinical trial of itsinvestigational oral PD-L1 inhibitor, OX-4224, in patients with...
-
1 week ago | 
pipelinereview.com | Ulrich Martin
~ New data show AAV-delivered antibody fragments targeting oxidized phosphatidylcholines (PC-OxPL), a species of oxidized phospholipids, thereby neutralizing TDP-43 pathology and motor neuron toxicity in ALS models ~ ~ Underscores potential of VTx-001 to act on upstream drivers of ALS ~ AMSTERDAM, The Netherlands & BOSTON, MA, USA I May 07, 2025 I VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases,...
-
1 week ago | 
pipelinereview.com | Ulrich Martin
Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results will be shared with regulatory authorities TOKYO, Japan & BASKING RIDGE, NJ, USA I May 07, 2025 I Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically...
-
1 week ago | 
pipelinereview.com | Ulrich Martin
-Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- – ABO21009’s unique mechanism of action depletes pathogenic T and B cells, induces expansion of Tregs for lasting efficacy, and preserves overall immunity- GOSSELIES, Belgium and NANTES, France I May 7, 2025 I AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory...
